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Chapel Hill, North Carolina; and 3Northwestern University Feinberg School of Medicine, Chicago, IllinoisChronic digestive diseases, including irritable bowel
syndrome, gastroesophageal reflux disease, and inflam-
matory bowel diseases, cannot be disentangled from their
psychological context—the substantial burden of these
diseases is co-determined by symptom and disease
severity and the ability of patients to cope with their
symptoms without significant interruption to daily life.
The growing field of psychogastroenterology focuses on the
application of scientifically based psychological principles
and techniques to the alleviation of digestive symptoms. In
this Clinical Practice Update, we describe the structure and
efficacy of 2 major classes of psychotherapy—cognitive
behavior therapy and gut-directed hypnotherapy. We focus
on the impact of these brain–gut psychotherapies on
gastrointestinal symptoms, as well as their ability to
facilitate improved coping, resilience, and self-regulation.
The importance of the gastroenterologist in the promo-
tion of integrated psychological care cannot be overstated,
and recommendations are provided on how to address
psychological issues and make an effective referral for
brain–gut psychotherapy in routine practice.Keywords: Brain-gut Psychotherapy; GI Psychologist;
Gut-directed hypnotherapy; Cognitive Behavior Therapy.
hronic digestive disorders cost the health careCsystem billions of dollars and are associated with
substantial disease burden.1 The burden of these diseases is
co-determined by symptom/disease severity and the ability
of patients to cope with their symptoms without significant
interruption to daily life. In other words, chronic digestive
diseases cannot be disentangled from their psychosocial
context. The most common chronic digestive disorders are
the functional gastrointestinal (GI) and motility disorders,
the burdens of which are amplified when symptoms are
severe or refractory, psychiatric comorbidity is present,
and/or coping skills are impaired.2 Patients with reflux
hypersensitivity and functional heartburn acquire risk from
the unnecessary long-term use of PPIs when esophageal
hypervigilance overshadows symptom-reflux correlation.3,4
Irritable bowel syndrome (IBS) can progress into severely
disabling centrally mediated abdominal pain syndrome5;
and psychosocial factors, when coupled with opiate use,
increase risk of narcotic bowel syndrome.6,7 The burden of
“organic” conditions, such as Crohn’s disease and ulcerative
colitis, is similarly amplified by psychosocial factors and
poor coping. Indeed, 15% of patients with inflammatorybowel disease (IBD) account for approximately 50% of
health care expenditures, which appears to be driven by
concomitant chronic pain, depression, and poor social
support.8,9 Depression, when present in IBD, has been
shown to increase risk for surgery, hospitalizations, and
disability, and may contribute to disease flare.10
Brain–gut psychotherapies, including cognitive-behavior
therapy (CBT) and gut-directed hypnotherapy, are opti-
mally delivered by mental health professionals specializing in
psychogastroenterology, a field dedicated to applying effec-
tive psychological techniques to GI problems. These therapies
have the capacity to reduce health care utilization and
symptom burden,2,11,12 especially when they are integrated
directly into GI practice settings.9,13,14 Specifically, brain–gut
psychotherapies work on 2 related pathways—they target
abdominal pain, visceral hypersensitivity, and GI motility;
and/or facilitate improved coping, resilience, and self-
regulation skills.11 Without a gastroenterologist’s strong,
compelling recommendation for these effective therapies and
his/her knowledge about how to successfully facilitate
referrals for such treatments, many patients do not receive
care at all,13 or do so too late in the process, when self-
management has failed and refractory psychopathology
and/or inflammatory disease have developed.2 There is also
mounting evidence that stress has important and commonly
deleterious effects on gut function through neural-, immune-,
and microbiome-related interactions.15 Table 1 summarizes
the best practices for promoting the use of brain–gut
psychotherapies in routine GI care for best clinical outcomes.
Best Practice Advice 1: Gastroenterologists should
routinely assess health-related quality of life, symptom-
specific anxiety, early life adversity, and functional
impairment as these relate to a patient’s digestive
symptoms.
Individuals with GI disorders tend to have significantly
impaired quality of life (QOL) compared to the general
population,16–18 with IBS patients in particular demon-
strating lower QOL than patients with end-stage renal
disease and diabetes.19 Across functional and organic
diseases alike, the most pronounced impact of GI symptoms
Table 1.Best Practice Update: Incorporating Psychogastroenterology Into Management of Digestive Disorders
Description The current review provides the reader with a framework to understand the scientific rationale and best practices
associated with incorporating brain–gut psychotherapies into routine GI care. We discuss how
gastroenterologists can employ state-of-the-art assessment and referral techniques that ensure a tailored,
precision-medicine behavioral care pathway into their unique practice settings, across the full spectrum of
digestive disease.
Methods These practice updates come from review of the literature, including existing systematic reviews and expert opinion.
Best Practice Advice
1 Gastroenterologists should routinely assess health-related QOL, symptom-specific anxieties, early life adversity, and
functional impairment related to a patient’s digestive symptoms.
2 Gastroenterologists should master patient-friendly language on the following topics: the brain–gut pathway and how
this pathway can become dysregulated by any number of factors; the psychosocial risk, perpetuating, and
maintaining factors of GI diseases; and why the gastroenterologist is referring a patient to a mental health
provider.
3 Gastroenterologists should know the structure and core features of the most effective brain–gut psychotherapies.
4 Gastroenterologists should establish a direct referral and ongoing communication pathway with 1–2 qualified mental
health providers and assure patients that he or she will remain part of their care team.
5 Gastroenterologists should familiarize themselves with 1 or 2 neuromodulators that can be used to augment
behavioral therapies when necessary.on QOL include fatigue, limitation of life activities, and
pain.19 The impact of GI disorders on QOL, including which
domains of QOL are affected, varies greatly among patients
with the same diagnosis, even when disease history, loca-
tion, severity, or medical therapies are similar. QOL is
largely dependent on individual differences in coping
and resilience, as well as the experience of GI-specific
anxiety, need for lifestyle adaptations, and stress. Patients
with substantial GI-related life impact may need more, or
differently targeted, medical interventions than other
patients with the same diagnoses, and routine assessment of
life impact and distress associated with GI symptoms could
identify patients in need of extra support early on in care.
Assessment of health-related QOL can be informal and
brief, using 1–2 open-ended questions that invite the patient
to provide the most relevant information about the life
impact of the physical symptoms, for example, “How do
your bowel symptoms interfere with your ability to do what
you want to do in your daily life?” and “What areas of your
life are affected most?” These simple questions often elicit
valuable information about the particular domains of the
patient’s life that are most affected by GI problems. There
are multiple benefits to this approach:
1. Without an open-ended option, the physician may
remain unaware of key areas where targeted medical
intervention can be of greatest help for restoring
satisfactory life functioning.
2. These questions about life impact build rapport by
indicating to patients that their doctor is aware of,
and interested in, the burden of their illness.
3. The patients’ responses to open-ended queries about
life impact of symptoms can also provide useful
comparison data points for rechecking later to assess
the effectiveness of interventions in improving the
domains that are most important to his/her life and
well-being (eg, “Did you make it out on the boat
this summer?”). This gives a more complete pictureof true progress in managing the patient’s health
problem than does information about changes in
frequency or type of digestive tract symptoms alone.
4. Impact questions can identify patients who clearly
need help from a behavioral health professionals to
cope more effectively with their illness—when a
referral to a GI psychologist is proposed specifically to
help improve QOL, it is more likely to be well
received.
Asking about early life adversity to understand whether
the patient had a personal history of physical, emotional, or
sexual abuse; witnessed domestic violence in their household
growing up; was raised by a caregiver with a substance abuse
problem or mental illness; or had a family member who was
incarcerated, could identify critical factors affecting the
onset and expression of functional GI disorder symptoms20
and point out which patients would benefit from psycho-
logical intervention earlier on in care. One commonly used
screening questionnaire for early life adversity is the Adverse
Childhood Experience Questionnaire.21
Symptom-specific anxiety can also amplify disease
burden and lead to higher health care utilization.22,23 A
survey of 1242 IBS patients24 found, for example, that a
substantial minority of the patients thought that their dis-
orders could develop into colitis (43%) or cancer (21%). In
IBD, patients are worried about the effect of biologic ther-
apies or surgery; that pain indicates flare, obstruction, or
perforation; or about their risk of infertility.25,26 These
concerns or fears can be uncovered by asking a simple and
direct open-ended question: “What worries or concerns do
you have about your symptoms?,” which can yield an
important opportunity for education and reassurance.
Eliciting and discussing whatever worries and concerns the
patient has about his or her condition can also help identify
instances where excessive anxiety, catastrophizing, or
depressive symptoms weigh so heavily in the patient’s dis-
ease experience that a referral to a behavioral health care
provider is needed.
For certain disorders, disease-specific QOL question-
naires (such as the Irritable Bowel Syndrome Quality of 
Life27 and the Inflammatory Bowel Disease Questionnaire28) 
can be useful clinical aids for quantifying the current impact 
of the disease on patients’ lives. If it is feasible to incorpo-
rate such measures routinely into clinic visits, the scores 
they provide are another important means of identifying 
and addressing marked QOL impact of the disease and how 
it changes in response to interventions. In contrast, general 
QOL measures like the 36-Item Short-Form Health Survey29 
are typically not very clinically useful in GI care, as it is 
unclear whether poor scores are attributable to the GI dis-
order or something else, and as they are also less likely to 
reflect treatment response well. Routine screening for 
depression and anxiety is not required for the general GI 
population but may be helpful in special, high-risk pop-
ulations, including IBD.30 For some patients who exhibit 
such symptoms, a quick measurement to assess their clinical 
significance may be helpful. Brief questionnaires, such as the 
free-to-use Patient Health Questionnaire-931 for depression, 
are useful to have on hand for this purpose. The National 
Institutes of Health–supported PROMIS (Patient-Reported 
Outcomes Measurement Information System) screening 
tools are also free, and may be useful when patients are 
being screened in comparison to the general population (eg, 
such as in primary care).32
Best Practice Advice 2: Gastroenterologists should 
master patient-friendly language on the following 
related topics: bi-directional brain–gut pathway and 
how this pathway can become dysregulated by any 
number of factors; psychosocial factors that perpetuate 
or exacerbate GI symptoms regardless of original eti-
ology; and why the gastroenterologist is referring a 
patient to a mental health provider.
Research has increasingly elucidated the important role 
of the central nervous system’s neural, hormonal, and 
immunological bi-directional communication with the gut in 
maintaining normal GI functioning and modulating disease 
activity.33,34 The brain–gut communication pathway is notTable 2.Key Points in Patient Education About the Brain–Gut A
In recent years, we have learned that the brain and the intestines are muc
actually plays a big role in keeping the functioning of the intestines
1. The brain and the gut (intestines) communicate with each other
2. The intestines send frequent messages to the brain to let the brain
to have a bowel movement.
3. The brain usually dampens these nerve signals coming from the i
conscious awareness most of the time.
4. The brain sends frequent messages to the intestines, both in resp
activity of gut muscles, secretion of acid and fluids in the gut, and
the best way according to what is going on inside them and our liv
expected and instructing the intestines to inhibit its digestive ac
5. This normal brain–gut communication can sometimes go wrong
extended time, such as very substantial life stress, strong negativ
can also make the normal brain–gut communication go awry. Wh
the gut more strongly than usual and may start sending inappro
Because the brain is a part of the control system of the gut, it is often po
regardless of whether it is actively contributing to making the symptoms
example, CBT or gut-directed hypnosis, and also with medications thaonly an important concept in functional disorders, where it
is typically discussed most, but in all GI disorders. Chronic
stress and emotional distress impair the ability of the body
to control inflammation,35 which increases risk of both pe-
ripheral and central pain sensitization in the GI in general,
and can affect symptom status and clinical outcomes in
disorders, including IBD,36 gastroesophageal reflux disease,
and peptic ulcer disease.37 Even though the details are
complicated, the basic concept of this brain–gut communi-
cation pathway is fairly simple and provides a foundation
for understanding many aspects of GI health problems and
their treatment. See Table 2 for essential components of a
patient-friendly brain–gut explanation.
Educating patients about the brain–gut axis early in the
relationship is helpful so that they do not perceive this as
being brought up only after everything else has failed, with
the implication of solely a psychological cause of symptoms.
If, as is often the case, the conventional medications or
treatment approach produce an unsatisfactory degree of
relief, this framework gives patients a clear rationale for
alternative approaches. Psychological interventions, such as
CBT or gut-directed hypnosis, make good sense as GI in-
terventions when explained in the context of a dynamic and
continually active brain–gut communication pathway. Self-
regulatory and self-care methods, such as meditation,
relaxation, yoga, and physical exercise, can also be an inte-
gral part of GI health. Additionally, the gut–brain pathway
can provide an explanation for inflammatory-related mood
and stress effects, and the need for neuromodulation to
counteract the impact on the brain from GI pathology.Conceptualizing the Behavioral
Factors That Perpetuate or
Exacerbate Gastrointestinal Symptoms
Regardless of Original Etiology
Educating patients about behavioral factors that can
exacerbate and perpetuate a health problem is oftenxis, in Lay Language
h more closely connected than was previously thought, and the brain
normal and healthy.
continually through nerves and chemical signals.
know about their condition, such as fullness from a meal or the need
ntestines so they are not uncomfortable, and keeps them outside our
onse to these internal messages from the gut and also to help tune the
immune activity, to help the intestines coordinate their functioning in
es (eg, telling the gut to increase stomach acid secretion when food is
tivity during physical exercise).
when something disturbs the brain or the nervous system for an
e emotions, or inadequate sleep. Inflammation or infection in the body
en that happens, for any reason, the brain perceives sensations from
priate signals down to the gut that disturb intestinal functioning.
ssible to get it to help reduce the intestinal disturbance and symptoms
happen. This can be done by specialized psychological treatment, for
t make the brain less sensitive to input from the intestines.
necessary. A physical GI problem may seem to the 
average person to be something relatively isolated 
from the conditions of daily life and outside of his/her 
control. In reality, however, stress, poor quality and 
inadequate quantity of sleep, maladaptive eating patterns 
(like consuming large meals or eating late at night), 
and lack of physical activity are potent symptom con-
tributors to a range of health problems—behaviorally, 
these perpetuating and maintaining factors are within 
the patient’s control and can be adjusted. It should 
also be emphasized with patients that even though these 
and other behavioral and psychosocial contributing fac-
tors may exacerbate symptoms and can be changed to 
attenuate the disease severity, they are generally not 
the causes of the GI disease. It is also helpful to remind 
patients that most health problems are multifactorial 
and that there is unlikely to be a single solution, at least 
long-term. As a result, introducing the concept of 
routine referral to a mental health care provider early in 
the evaluation will be better received. Similarly, factors 
that initiate a disease process (inflammation or immune 
dysregulation, surgery, stress) do not always remain 
active, despite ongoing symptoms. Models where this can 
be illustrated well include post-infectious IBS and IBD 
with functional overlap, both common conditions with 
etiologies that differ from their maintaining factors.38,39 
Highlighting these models can allow patients to move 
past looking for a cause or explanation for why they are 
symptomatic (eg, infection they got, surgery they had) 
toward solutions that they can act upon (eg, diet, lifestyle, 
stress, adherence). 
Why the Gastroenterologist Is
Referring a Patient to a Mental
Health Provider
One of the most difficult parts of providing behavioral 
medicine treatments for patients presenting with GI 
complaints in the outpatient office is helping the patients 
to understand why they are being referred to a psychol-
ogist for a GI symptom. If this is not done correctly, many 
patients will believe the physician is discounting their 
physical symptoms and believes that the patient’s 
symptoms are imagined or all psychologically based. 
Failure to properly explain the reason for referral will 
lead to poor follow through and will likely lead the 
patient to seek care with another provider. Furthermore, 
this failure can negatively impact what is an otherwise 
good physician–patient relationship, and decrease the 
likelihood of successful symptom control. It is also 
important to recognize that, as the physician, you do not 
need to decide on the specific type of behavior therapy
the patient will benefit from—this is usually best decided 
by the behavioral health care provider. See Table 3 for 
key patient education points for accomplishing effective 
referral to a psychologist.GI psychologists are licensed providers with a doctoral
degree in their profession who fall under the American
Psychological Association’s recognized subspecialty of
clinical health psychology, an area of psychology
devoted to the application of psychological principles to
medical conditions and to the integration of
psychologists into medical settings and multidisciplinary
teams. Health psychologists can develop further
expertise working within a specific medical subspecialty
(GI, obstetrics/gynecology, oncology, pain) or practice
as generalists. Generalists are often pleased to see
patients with GI conditions, and will usually seek out
either specialized training in GI or read the literature on
the disease they are treating and its effective treatment
approaches. Psychiatrists are medical doctors focused
on determining a patient’s specific psychiatric diagnosis
and remediating symptoms with psychotropic
medication. A smaller subset of psychiatrists specialize
in psychosomatic medicine and are a welcome addition
to a multidisciplinary GI team. The Rome Foundation
has recently created an internationally based
psychogastroenterology section that brings together
health care professionals with clinical and/or research
interests in this growing subspecialty—psychologists,
gastroenterologists, psychiatrists, internists/pediatricians
with psychosomatic interests, as well as non-doctorally
trained providers such as nurses, nurse practitioners,
physician assistants and social workers, to facilitate
best clinical and research practices in this evolving field.
Future directions in this area may include establishing
core competencies or necessary training credentials for
the practice of psychogastroenterology.
Best Practice Advice 3: Gastroenterologists should
know the structure and core features of the most
effective brain–gut psychotherapies.
Brain–gut psychotherapies are those that leverage the
brain’s ability to bring under voluntary control those
symptom processes that seem, initially, to be driven
completely by the gut. Brain–gut psychotherapies share
several important features that distinguish them from
traditional psychotherapy approaches—they are typically
short-term and GI symptom–focused; and patients with
comorbid chronic depression or anxiety are typically not
good candidates. These therapies offer the best results when
delivered by a health psychologist or other medically
trained mental health provider who is familiar with the
physiological basis of symptoms and the goals of the
medical team. Brain–gut therapies are skills-based and
focus specifically on the down-regulation of unpleasant GI
sensations, decreasing avoidance behaviors associated with
fear of having symptoms and building coping and resilience
to stress or lifestyle changes imposed by a chronic condi-
tion. These therapies differ from more traditional forms of
psychotherapy, which focus on providing support, normal-
izing psychopathology, and/or facilitating insight into the
reason the patient is experiencing symptoms. Another
benefit of these skills-based therapies is that their impact
can be durable long after therapy is discontinued, making
Table 3.Key Points in Patient Education About a Referral to a Mental Health Provider, From the Perspective of a
Gastroenterologist, in Lay Language
Once the patient understands the brain–gut connection, you can shift attention to the therapies that work on this pathway.
1. Introduce the concept of neuromodulation and discuss how medications. such as low-dose antidepressants and anti-seizure
medications, can alter neurologic transmission of signals to the brain and dampen some of the discomfort they are feeling.
 Cons of the medications including their side effects; limited efficacy, especially when compared to behavioral therapies; and that
most patients will need to commit to these medications long-term.
2. When introducing the concept of the patient undergoing hypnosis or cognitive therapy, bring up a few examples to help the patient
understand the biologic reasoning behind the treatments.
 One way to describe the connection is to discuss how their GI tract is always moving through peristalsis and accommodation, but the
brain’s normal job is to prevent you from feeling this movement because feeling your GI tract all day would be too distracting. You can
compare this to putting on a watch or your glasses in that you feel it when you put them on to make sure they are correctly placed, but
after a minute or so your brain will not pay attention to this signal—this is a healthy mechanism the brain has developed so that you
can focus your attention on important tasks at hand.
 This process of filtering out non-essential sensations is extremely important but very complex and poorly understood. Psychological
therapies can help you divert your brain’s attention away from the symptoms, can help you to be less bothered by your symptoms
and allow you to focus on more important things.
3. Stay basic in terms of the effects and potential mechanisms of brain–gut psychotherapies. This basic information sets the stage for a
much more informed visit with the psychologist and dispels the pretense that the GI doctor thinks that the patient has nothing wrong.
 You can say that CBT provides patients with a skill set that helps them change the way they view their symptoms, or to make their
symptoms feel less threatening.
 Hypnosis is not like a stage entertainment show and is nothing magical—it is a real medical therapy that has been studied with great
outcomes.
 There are no side effects to these therapies, and the positive effects on symptoms often last for years.them cost-effective over the long-term when compared to
psychotropics.40 For a recent review of brain–gut psycho-
therapies in IBS and IBD, see Ballou and Keefer.11 IBS
patients in particular often appreciate hearing that there
are more than 30 randomized controlled trials for CBT and
11 for hypnosis in IBS alone, with numbers needed to treat
between 2 and 4.12 These therapies have also been used
successfully across a spectrum of digestive diseases,
including non-cardiac chest pain, functional dyspepsia,
gastroesophageal reflux disease, and IBD.
CBT is one of the most robust, well-tested, brain–gut
psychotherapies, with more than 30 randomized
controlled trials and a number needed to treat of 3.12 CBT
focuses on remediating an individual’s maladaptive or
“unhelpful” thoughts, feelings, and behaviors as they relate
to any number of symptoms, rather than identifying a root
cause or initiating event. CBT has been used successfully for
depressed teenagers with IBD,41–44 and as a way to augment
self-management behavior for patients with Crohn’s dis-
ease.45 It has been effectively delivered by nurses,46 over
the telephone,47 and in groups.48 CBT for functional GI
disorders, including those seen in the context of IBD, targets
the specific maladaptive cognitive-affective processes
known to impact GI symptom experience at the level of the
brain49—these include catastrophizing, cognitive inflexi-
bility, fear of symptoms, or hypervigilance/attentional bias
to benign gut sensations. Depending on a patient’s GI
symptom profile, various forms of skills remediation can be
used, including diaphragmatic breathing, cognitive restruc-
turing, or learning new problem-solving skills. CBT for IBS
can now be delivered with efficacy equivalent to longer
treatment courses, in as few as 4 therapy sessions,50 and has
shown promise when delivered online for both IBS and
IBD.51–54 Elements of CBT, particularly diaphragmatic
breathing, have been used for esophageal conditions,including rumination disorder and supragastric belch-
ing.14,55 Building up a tolerance to unpleasant GI symptoms
through interoceptive exposure, another CBT technique,
with and without mindfulness,53,56,57 has also been used
successfully in patients with symptom-specific anxiety.58
Gut-directed hypnotherapy is also a well-tested therapy
for a range of pediatric and adult GI disorders, including IBS
(>11 randomized controlled trials), heartburn, and IBD.59
Targets of hypnotherapy include visceral hypersensitivity,
motility disturbance, hypervigilance to benign sensations,
and somatization. Two protocols in particular, the 7-session
North Carolina Protocol60 and the 12-session Manchester
protocol61 have demonstrated similar benefits in refractory
IBS, with up to 80% of patients acquiring at least a 50%
reduction in IBS Severity Scoring.62,63 The fully scripted
North Carolina Protocol has been delivered as a home-based
therapy64 and has also been validated for use with gastro-
esophageal reflux65 and ulcerative colitis,66 and is particu-
larly useful for enabling less-experienced providers to
successfully deliver gut-directed hypnotherapy.67
Best Practice Advice 4: Gastroenterologists should
establish a direct referral and ongoing communication
pathway with 1–2 qualified mental health providers
and assure patients that he or she will remain part of
their care team.
Access to evidence-based brain–gut psychotherapies
limits their utility and, while not every gastroenterologist
will know of a GI health psychologist, a viable alternative is
to reach out to the state psychological society (eg, [state
name] Psychological Association) or to a national registry
for the names of therapists who are interested in seeing GI
patients and who are familiar with at least one of the
evidence-based brain–gut psychotherapies. The typical
toolbox of someone equipped to see GI patients include
experience with medical populations or chronic illness;
collaborates with physicians; has been trained under a 
cognitive-behavioral theoretical orientation; has a collabo-
rative, active patient interaction style; practices 1 or more of 
the evidence-based brain–gut psychotherapies; and, if he or 
she practices hypnotherapy, their training was provided 
through a reputable organization focused on training health 
professionals. Having a clear referral and communication 
pathway improves outcomes by establishing buy-in on the 
part of the patient (they are not just left to find a mental 
health provider on their own), and ensures that the focus of 
treatment will be the GI condition. The mental health pro-
vider should feel free to call and ask the GI doctor questions 
around the patient’s symptoms, workup, and medical 
recommendations. GI doctors should expect to receive a 
copy of the patient’s psychological intake report and 
possibly a final treatment summary. The GI doctors should 
also plan to see the patient themselves sometime during the 
course of active psychotherapy as a way to maintain conti-
nuity of care, reinforce therapy gains, change or reduce 
medication use, and troubleshoot any challenges.
Contrary to what many people assume, the presence of 
significant psychological distress does not suggest suit-
ability for referral to a GI psychologist. Research has shown 
that many of the brain–gut psychotherapies are less effec-
tive when a patient has comorbid psychopathology.68 If GI 
patients have comorbid Axis I disorders and suffer fromTable 4.List of Readings to Enhance Understanding of Best Pr
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have those problems addressed first, either by a more
general psychologist in the community who focuses on
depression and anxiety disorders, or by means of psycho-
tropic medications, as this will often improve the odds of the
patients subsequently benefitting from GI-focused psycho-
logical treatment. For patients with more moderate
emotional symptoms, however, the affective disorders
can be addressed in parallel with the work of the GI
psychologist. Along these lines, it is helpful for gastroen-
terologists to have information on a wide range of mental
health resources, including free or sliding-scale programs, in
their communities to ensure appropriate mental health
system access for these patients.
Best Practice Advice 5: Gastroenterologists should
familiarize themselves with 1 or 2 neuromodulators
that can complement behavioral therapies when
necessary.
Neuromodulation/psychotropic use is sometimes
necessary and often effective in chronic digestive diseases2
and should be on the radar of practicing gastroenterologists,
especially given a shortage of qualified psychiatrists. In
keeping with the patient-friendly, de-stigmatizing rationale
for brain–gut psychotherapies, there may be scenarios in
which a health psychologist and gastroenterologist are
comfortable that the introduction of a neuromodulator,actice Advice
Associated BPA
troenterol 2011;106:14–25. 1
g yourself. How to improve the patient
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ithin Our Bodies Impacts Our Mood, Our
BN: 978-0062376558.
particularly a selective serotonin reuptake inhibitor; 
serotonin and norepinephrine reuptake inhibitor; or tricy-
clic antidepressant, could augment ongoing behavior ther-
apy. Common reasons include a diagnosis of a minor 
comorbid depression or anxiety disorder, lack of insight or 
motivation that precludes participation in in psychological 
treatment, or chronic pain that is not responding fully to 
behavioral intervention. See Sobin et al69 for a primer in 
central neuromodulation for functional GI disorders and 
Thorkelson et al70 for similar information in IBD.Summary and Future Directions
The importance of the gastroenterologist in the promo-
tion of psychogastroenterology cannot be overstated. We 
have discussed best practices for the assessment and 
referral of patients across the spectrum of disease to brain–
gut psychotherapies, including CBT and gut-directed 
hypnotherapy. There are research and clinical gaps that 
will need to be addressed in order to foster widespread 
integration of these services. From a research perspective, 
gaps include lack of comparative effectiveness trials that 
compare brain–gut psychotherapies against each other and/
or against psychotropic medications and lack of sufficient 
research to date of other promising brain–gut therapies, 
such as mindfulness meditation71 or acceptance-based 
approaches.72 There are only a few studies supporting the 
impact of brain–gut psychotherapies on actual disease 
course or inflammation in conditions such as Crohn’s 
disease and ulcerative colitis,66,73,74 and limited studies 
demonstrating the utility of brain–gut psychotherapies in 
accelerating or enhancing the efficacy of pharmacologic 
therapies. Clinical gaps include need for better coverage for 
these therapies by insurance—health psychologists can be 
reimbursed for health and behavior codes for treating these 
conditions (Current Procedural Terminology codes 96150/ 
96152), but there are restrictions on which other types of 
professionals can use them. Medicare and commercial in-
surance plans often cover the cost of services, but many 
providers are out of network or do not accept insurance. It 
is sometimes helpful to remind patients, however, that these 
highly effective therapies are short term (usually less than 
3 months) and have a one-time total cost between $1000 
and $2000 out of pocket. The effects of these treatments are 
commonly durable for several years and therapy usually 
does not need to be re-administered. If you point out to 
patients that what they pay out of pocket per month for 
other generally less effective uncovered interventions, such 
as probiotics, herbs, special diets, colonic cleanses, then the 
out-of-pocket expense often becomes of less concern. 
Research demonstrating the cost-effectiveness of these 
therapies is underway and may lead to wider adoption of 
these services by accountable care organizations, payors, 
employers, and other stakeholders. Lastly, there is a need 
for more trained providers and the expansion of remote, 
online, or digitally based brain–gut therapies that could 
offset overhead and other therapy costs. For a list of addi-
tional readings in this important area, please see Table 4.References
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